Evaluation of ERK as a therapeutic target in acute myelogenous leukemia A novel ERK inhibitor for AML

Eitemau Tebyg

• Effects of the multi‐kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia
  gan: Weisberg, Ellen, et al.
  Cyhoeddwyd: (2020)
• The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations
  gan: Weisberg, Ellen, et al.
  Cyhoeddwyd: (2020)
• Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT and FLT3 in hematologic malignancies: Mutant KIT and FLT3 response to Tyrosine Kinase Inhibitors
  gan: Weisberg, Ellen, et al.
  Cyhoeddwyd: (2019)
• Inhibition of the deubiquitinase USP10 induces degradation of SYK
  gan: Yang, Jing, et al.
  Cyhoeddwyd: (2020)
• Repurposing of Kinase Inhibitors for Treatment of COVID-19
  gan: Weisberg, Ellen, et al.
  Cyhoeddwyd: (2020)